generic speaker image
Claire de Oliveira, PhD - Canadian Partnership Against Cancer. Toronto, ON, CA

Claire de Oliveira, PhD Claire de Oliveira, PhD

Expert Advisor, Cancer Economics | Canadian Partnership Against Cancer

Toronto, ON, CANADA

Dr. Claire de Oliveira's main areas include the quantification of the economic burden and the assessment of value for money.





loading image loading image loading image





Dr. Claire de Oliveira joined the Canadian Partnership Against Cancer as Expert Advisor, Cancer Economics in 2016. In this role, she develops health economics expertise within the Partnership and supports efforts to deepen the capacity to quantify the burden of cancer and assess the economic impact of a coordinated, pan-Canadian approach to cancer control. She also works across cancer control initiatives to quantify efficiencies and support efforts to improve the sustainability of the cancer control system.

In addition to her work at the Partnership, Dr. de Oliveira is a Reader in Health Economics at the Centre for Health Economics and the Hull York Medical School at the University of York, UK, Health Economist at the Centre for Addiction and Mental Health, Associate Professor at the Institute of Health Policy, Management and Evaluation at the University of Toronto, and Adjunct Scientist at ICES. Her main areas of research in the cancer domain include the development of costing methodology, the measurement of the economic burden, and the assessment of value for money in cancer care.

Dr. de Oliveira holds membership with the Canadian Centre for Applied Research in Cancer Control and is one of the program leads for Health Technology Assessment. In addition, she is a collaborator at the Toronto Health Economics Technology Assessment Collaborative. Dr. de Oliveira holds a Masters of Arts degree and a Doctorate degree in economics from McMaster University. She also holds a licentiate degree in economics from the University of Oporto in Portugal.

Areas of Expertise (6)


Health Economics

Health Services Research

Health Policy

Mental Health

Child Health

Education (2)

McMaster University: PhD, Economics 2008

McMaster University: MA, Economics 2004

Affiliations (4)

  • Canadian Centre for Applied Research in Cancer Control: Member
  • Canadian Centre for Applied Research in Cancer Control: Program Lead, Health Technology Assessment
  • Insititute for Health Policy, Management and Evaluation, University of Toronto: Assistant Professor
  • Institute for Clinical Evaluative Sciences: Adjunct Scientist

Articles (9)

Phase-specific and lifetime costs of cancer care in Ontario, Canada

BMC Cancer

2016 Cancer is a major public health issue and represents a significant economic burden to health care systems worldwide. The objective of this analysis was to estimate phase-specific, 5-year and lifetime net costs for the 21 most prevalent cancer sites, and remaining tumour sites combined, in Ontario, Canada.

view more

Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study


2013 Cancer incidence and treatment-related costs are rising in Canada. We estimated health care use and costs in the first year after diagnosis for patients with 7 common types of cancer in Ontario to examine temporal trends in patterns of care and costs...

view more

Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study


2013 The first year after cancer diagnosis is a period of intensive treatment and high cost. We sought to estimate costs for the 21 most common cancers in Ontario in the 3-month period before and the first year after diagnosis...

view more

The Out-of-Pocket Cost Burden of Cancer Care-A Systematic Literature Review


Nicolas Iragorri, Claire de Oliveira, Natalie Fitzgerald, Beverley Essue


Abstract Background: Out-of-pocket costs pose a substantial economic burden to cancer patients and their families. The purpose of this study was to evaluate the literature on out-of-pocket costs of cancer care.

view more

The Indirect Cost Burden of Cancer Care in Canada: A Systematic Literature Review


Nicolas Iragorri, Claire de Oliveira, Natalie Fitzgerald, Beverley Essue


Abstract Background and objectives: Cancer poses a substantial health and economic burden on patients and caregivers in Canada. Previous reviews have estimated the indirect cost burden as work-related productivity losses associated with cancer. However, these estimates require updating and complementing with more comprehensive data that include relevant dimensions beyond labor market costs, such as patient time, lost leisure time and home productivity losses.

view more

The psychosocial cost burden of cancer: A systematic literature review


Beverley M Essue, Nicolas Iragorri, Natalie Fitzgerald, Claire de Oliveira


Abstract Background and objective: Psychosocial costs, or quality of life costs, account for psychological distress, pain, suffering and other negative experiences associated with cancer. They contribute to the overall economic burden of cancer that patients experience. But this category of costs remains poorly understood. This hinders opportunities to make the best cancer control policy decisions. This study explored the psychosocial cost burden associated with cancer, how studies measure psychosocial costs and the impact of this burden.

view more

Temporal trends in place of death for end-of-life patients: Evidence from Toronto, Canada


Zhuolu Sun, Denise N Guerriere, Claire de Oliveira, Peter C Coyte


Abstract Understanding the temporal trends in the place of death among patients in receipt of home-based palliative care can help direct health policies and planning of health resources. This paper aims to assess the temporal trends in place of death and its determinants over the past decade for patients receiving home-based palliative care. This paper also examines the impact of early referral to home-based palliative care services on patient's place of death. Survey data collected in a home-based end-of-life care program in Toronto, Canada from 2005 to 2015 were analysed using a multivariate logistic model.

view more

Comparing Childhood Cancer Care Costs in Two Canadian Provinces


Mary L McBride, Claire de Oliveira, Ross Duncan, Karen E Bremner, Ning Liu, Mark L Greenberg, Paul C Nathan, Paul C Rogers, Stuart J Peacock, Murray D Krahn


Background: Cancer in children presents unique issues for diagnosis, treatment and survivorship care. Phase-specific comparative cost estimates are important for informing healthcare planning. Objective: The aim of this paper is to compare direct medical costs of childhood cancer by phase of care in British Columbia (BC) and Ontario (ON).

view more

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration


Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira, Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai


Background: Oncology therapy is becoming increasingly more expensive and challenging the affordability and sustainability of drug programmes around the world. When new drugs are evaluated, health technology assessment organisations rely on clinical trials to inform funding decisions. However, clinical trials are not able to assess overall survival and generalises evidence in a real-world setting. As a result, policy makers have little information on whether drug funding decisions based on clinical trials ultimately yield the outcomes and value for money that might be expected.

view more